Pneumonia vaccine immune response study after spleen injury
Part of Immune system & allergy, Injuries & trauma clinical trials.
This trial studies how your immune system responds to a pneumonia (pneumococcal) vaccine after a spleen injury. It may help doctors better predict and improve protection in people recovering from splenic trauma.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old
- You have had a spleen injury from trauma
- You can take part in a vaccine/immune response testing plan set by the study team
- You are not expected to switch from non-surgical treatment to embolization or spleen removal after enrollment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a simple teaching program helps people who had their spleen removed understand their health needs better. It may help you take better care of yourself after surgery and get the right vaccinations.
This study looks at what factors can predict complications in people who do not have a functioning spleen, and how often those complications happen over time. It may help clinicians better identify higher-risk patients and improve care.
This trial tests whether a pneumococcal vaccine can help protect against a specific type of pneumonia bacteria. Researchers want to see if the vaccine can create antibodies that work against multiple strains.
This study tests a meningococcal B vaccine in adults who have had their spleen removed or have a spleen that doesn't work well (asplenia). It will compare how well the vaccine works in these patients versus healthy adults to see if it provides good protection.
This trial tests a single dose of a new pneumococcal vaccine (21-valent) in children and teens with sickle cell disease. It aims to see if the vaccine can help protect against serious infections caused by pneumococcus bacteria, which are especially dangerous for people with SCD.
This trial tests a new 23-valent pneumococcal vaccine to see if it safely protects healthy people against pneumonia and other infections caused by pneumococcal bacteria.
Hear when a new Asplenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.